AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Seekingalpha

Published November 10, 2026

Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated

Read the full story at Seekingalpha

Definium Therapeutics is a Hold, as risks from competition, regulatory shifts, and the niche nature of initial psychedelic therapy adoption.

Post on X

Share this story

Surfaced by 6 Google Alerts

Psychedelics
Psychedelic press release
Psychedelic biotech
Ibogaine
LSD
MDMA